Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pure MHC
Austin, Texas, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Pure MHC specializes in HLA target discovery for immunotherapy, providing novel peptide-HLA targets and TCR mimic antibodies for immuno-oncology and autoimmune research; partnered assets have not reported clinical results to date.
- Therapeutic areas
- OncologyInfectious DiseasesImmunology
- Modalities
- AntibodyAntibody-drug conjugateBispecific monoclonal antibodyPeptide
- Industry
- Biotech
02
Partnerships
AbbVie (licensing of targets for oncology and other disease indications)Myrio Therapeutics (antibody-based oncology therapeutics discovery)PhosImmune (development of TCR mimic antibodies for oncology)ImmunoScape (target discovery collaboration for multiple solid tumor indications)
Beyond the preview
Go deeper on Pure MHC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pure MHC.